Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.165 USD | +3.10% | -7.54% | +38.94% |
03-21 | Transcript : X4 Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 21, 2024 | |
03-21 | X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Sales 2024 * | 28.72M 2.3B | Sales 2025 * | 59.14M 4.73B | Capitalization | 196M 15.66B |
---|---|---|---|---|---|
Net income 2024 * | -94M -7.52B | Net income 2025 * | -107M -8.57B | EV / Sales 2024 * | 6.81 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.31 x |
P/E ratio 2024 * |
-2.58
x | P/E ratio 2025 * |
-2.6
x | Employees | 93 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.06% |
Latest transcript on X4 Pharmaceuticals, Inc.
1 day | +3.10% | ||
1 week | -7.54% | ||
Current month | -16.19% | ||
1 month | -19.66% | ||
3 months | +50.36% | ||
6 months | +53.49% | ||
Current year | +38.94% |
Managers | Title | Age | Since |
---|---|---|---|
Paula Ragan
FOU | Founder | 54 | 31/12/09 |
Adam Mostafa
DFI | Director of Finance/CFO | 44 | 31/08/18 |
Mary DiBiase
COO | Chief Operating Officer | 63 | 31/12/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Wyzga
CHM | Chairman | 69 | 30/06/18 |
David McGirr
BRD | Director/Board Member | 69 | 31/08/17 |
Paula Ragan
FOU | Founder | 54 | 31/12/09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +2.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 1.165 | +3.10% | 11,166,148 |
25/04/24 | 1.13 | -12.40% | 3,445,833 |
24/04/24 | 1.29 | +4.88% | 2,249,760 |
23/04/24 | 1.23 | -9.56% | 3,530,660 |
22/04/24 | 1.36 | +7.94% | 2,435,880 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.94% | 196M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- XFOR Stock